MedTrace Logo

Platelet Activation by a Collagen Analogue in Hemorrhagic Situations

NCT04483245 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2023-07-25

No results posted yet for this study

Summary

Dijon University Hospital and the Dijon-based NVH Medicinal Company have developed a recombinant mini-collagen NVH020B with platelet and Willebrand factor binding activity. Its small size and granular, non-fibrillar presentation make it suitable for use as an injectable hemostat in patients with a hemorrhage or other emergency under antiplatelet therapy.

Conditions

Interventions

BIOLOGICAL

Blood sampling

Blood sampling

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-07
Primary Completion
2023-04-11
Completion
2023-04-11

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04483245 on ClinicalTrials.gov